Why it matters
The federal government is explicitly funding infrastructure intended to make healthspan a clinically testable and potentially regulatable therapeutic target.
Decision implication
Track biomarkers, endpoint qualification, trial methods, regulatory precedents, and commercialization pathways created by PROSPR.
Who or what is affected
- ARPA-H
- PROSPR teams
- FDA/regulators
- research institutions
- healthspan industry
Evidence and sources
E5 — official federal source
P4L distinguishes the sourced event from the interpretation above. Participation, funding, proposed policy, or program inclusion does not by itself establish clinical effectiveness.
What P4L is watching next
- Milestones
- biomarker validation
- trial recruitment
- regulatory interactions
- published results.